Palivizumab prophylaxis against respiratory syncytial virus. Should its indications be reviewed? [1];Profilaxis con palivizumab frente al virus respiratorio sincitial: ¿Es necesario revisar sus indicaciones?

Anales de Pediatria

Volumn 60, Issue 1, 2004, Pages 87-88

  Salas Hernandez S ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB;

CHILD; DRUG INDICATION; GESTATIONAL AGE; HUMAN; INCIDENCE; INFECTION PREVENTION; LETTER; MEDICAL LITERATURE; PREVENTIVE MEDICINE; PROGNOSIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SPAIN; TREATMENT OUTCOME; VIRUS INFECTION;

EID: 1642326842     PISSN: 16954033     EISSN: None     Source Type: Journal    
DOI: 10.1157/13056016     Document Type: Letter

References (16)

1. Sue Simpson and Armando Burls. A West Midlands Development and Evaluation Service Report. A Systematic review of the effectiveness and cost-effectiveness of palivizumab (Synagis) in the prevention of respiratory syncytial virus (RSV) infection in infants at high risk of infection. Department of Public Health and Epidemiology. University of Birminghan, 2001.
2. Carbonell-Estrany X, Quero J, y Comité de Estándares de la Sociedad Española de Neonatología Recomendaciones para la prevención de la infección por virus respiratorio sincitial. An Esp Pediatr 2000;52:372-4.
3. Carbonell-Estrany X, J Quero J y Comité de Estándares de la Sociedad Española de Neonatología Recomendaciones para la prevención de la infección por Virus Respiratorio Sincitial: revisión. An Esp Pediatr 2002;56:334-6.
4. American Academy of Pediatrics. Prevention of Respiratory Syncytial Virus infections: Indications for the use of Palivizumab and update on the use of RSV-IGIV. Pediatrics 1998;5:1211-5.
5. The IMPACT-RSV STUDY GROUP. Palivizumab a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-7.
6. th ed. Red Book 2003;523-8.
7. Carbonell-Estrany X, Quero J, Bustos G, Cotero A, Doménech E, Figueras-Aloy J, et al. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study: IRIS Study Group. Pediatr Infect Dis J 2000;19:592-7.
8. Carbonell-Estrany X, Quero J, and IRIS Study Group: RSV hospitalization rates in premature infants born over two consecutive season. Pediatr Infect Dis J 2001;20:874-9.
9. Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J and the IRIS Study Group. Effect of Palivizumab prophilaxis in decreasing respiratory syncitial virus hospitalitations in premature infants Pediatr Infect Dis J 2003;22:823-7.
10. Moore TJ, Weis SR, Kaplan S, Blaisdell CJ. Reported adverse drugs events in infants and children under 2 years of age. Pediatrics 2002;110:1-5.
11. Moore TJ, Weis SR, Blaisdell CR. Reported fatal and serious adverse reactions associated with palivizumab. (abstract) Pediatr Acad Soc 2002. Available at: http://www.pas-meeting.org/2002 baltimore.
12. a B, Martinez Badás JP, Castañón Fernández L, Mallo Castaño J, Herrero Mendoza B, et al. Impacto potencial y análisis coste-eficacia de la profilaxis con palivizumab, en la prevención de bronquiolitis, en prematuros menores de 33 semanas de gestación. An Pediatr (Barc) 2003;59:328-33.
13. Danés Carreras I, Arnau de Bolos JM. Profilaxis de las infecciones por virus respiratorio sincitial con palivizumab. An Esp Pediatr 2002;56:289-91.
14. Joffe S, Ray GT, Escobar GJ, Black SB, Lien TA. Cost-efectiveness of respiratory syncytial virus prophilaxis among preterm infants. Pediatrcs 1999;104:419-27.
15. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Rehospitalization for respiratory syncytial virus among preterm infants Pediatrics 1999;104:894-9.
16. Frank W, Moler FW. RSV Immune Globulin Prophylaxis: Is an ounce of prevention worth a pound of cure? Pediatrics 1999;104:559.